Literature DB >> 12488796

VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis.

Ingela Nygren1, Anders Larsson, Anders Johansson, Håkan Askmark.   

Abstract

Homogenates of postmortem spinal cord from seven patients with amyotrophic lateral sclerosis (ALS) and six controls together with serum from 13 patients with ALS and 13 controls were analysed for vascular endothelial growth factor (VEGF) using an immunoassay (ELISA). There was no significant difference in VEGF levels in the spinal cord between the ALS patients and the controls. In serum the VEGF levels were significantly higher in the ALS group than in the control group. There was a moderate inverse relation between the duration of the disorder and the serum VEGF levels. The findings indicate that the capacity to synthesize VEGF is preserved even in the late stages of ALS. The results might also be consistent with a transient hypoxic component during the course of ALS, but not with a persistant spinal hypoxia in the late stages of the disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12488796     DOI: 10.1097/00001756-200212030-00007

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis.

Authors:  Hirotaka Tanaka; Masamitsu Shimazawa; Masafumi Takata; Hideo Kaneko; Kazuhiro Tsuruma; Tsunehiko Ikeda; Hitoshi Warita; Masashi Aoki; Mitsunori Yamada; Hitoshi Takahashi; Isao Hozumi; Hiroshi Minatsu; Takashi Inuzuka; Hideaki Hara
Journal:  J Neurol       Date:  2013-02-23       Impact factor: 4.849

2.  Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS.

Authors:  C Moreau; D Devos; V Brunaud-Danel; L Defebvre; T Perez; A Destée; A B Tonnel; Ph Lassalle; N Just
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

3.  Preserved expression of fibroblast growth factor (FGF)-2 and FGF receptor 1 in brain and spinal cord of amyotrophic lateral sclerosis patients.

Authors:  Susanne Petri; Klaus Krampfl; Kerstin Kuhlemann; Reinhard Dengler; Claudia Grothe
Journal:  Histochem Cell Biol       Date:  2008-12-19       Impact factor: 4.304

Review 4.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

5.  Angiogenin levels and ANG genotypes: dysregulation in amyotrophic lateral sclerosis.

Authors:  Russell Lewis McLaughlin; Julie Phukan; William McCormack; David S Lynch; Matthew Greenway; Simon Cronin; Jean Saunders; Agnieska Slowik; Barbara Tomik; Peter M Andersen; Daniel G Bradley; Phil Jakeman; Orla Hardiman
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

6.  Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients.

Authors:  Pawan K Gupta; Sudesh Prabhakar; Chandrika Abburi; Neel K Sharma; Akshay Anand
Journal:  J Neuroinflammation       Date:  2011-09-09       Impact factor: 8.322

7.  Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients.

Authors:  Pawan K Gupta; Sudesh Prabhakar; Suresh Sharma; Akshay Anand
Journal:  J Neuroinflammation       Date:  2011-05-13       Impact factor: 8.322

Review 8.  Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.

Authors:  Ana Catarina Pronto-Laborinho; Susana Pinto; Mamede de Carvalho
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

9.  Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study.

Authors:  Yang Hu; Chang Cao; Xiao-Yan Qin; Yun Yu; Jing Yuan; Yu Zhao; Yong Cheng
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

Review 10.  ALS and oxidative stress: the neurovascular scenario.

Authors:  Akshay Anand; Keshav Thakur; Pawan Kumar Gupta
Journal:  Oxid Med Cell Longev       Date:  2013-12-03       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.